NRSNW Latest Press Releases

-- October 13, 2026 --

NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones PRNewswire 8:31 AM

-- October 2, 2026 --

NeuroSense Provides Update on Nasdaq Listing Compliance PRNewswire 4:15 PM

-- September 25, 2026 --

NeuroSense Provides Business Update and Progress for the First Half of 2026 PRNewswire 4:30 PM

-- September 10, 2026 --

NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference PRNewswire 9:00 AM

-- July 22, 2026 --

NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS PRNewswire 8:30 AM

-- July 6, 2026 --

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS" PRNewswire 8:45 AM

-- June 29, 2026 --

NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS PRNewswire 9:30 AM

-- June 22, 2026 --

EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots PRNewswire 9:00 AM

-- June 11, 2026 --

NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS PRNewswire 9:00 AM

-- June 9, 2026 --

NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition PRNewswire 9:00 AM

Market Data Delayed 15 Minutes